drugset / Trial / NCT07675239

Comparison of Itraconazole With Itraconazole and Isotretinoin in the Treatment Duration, Safety a n d Cure Rate in Adult Patients of Tinea Corporis/ Cruris-A Randomised Controlled Trail

NCT07675239

Phase 4 Not yet recruiting 60 enrolled Pak Emirates Military Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Tinea corporis and tinea cruris are common superficial fungal infections that have become increasingly difficult to treat because of prolonged disease duration, frequent recurrences, and suboptimal response to standard antifungal therapy. Itraconazole is widely used for the treatment of dermatophytosis; however, treatment failures and relapses remain a significant concern. Isotretinoin has been proposed as an adjuvant therapy because of its effects on epidermal differentiation, keratinization, and follicular function, which may enhance antifungal penetration and improve treatment outcomes. This randomized controlled trial aims to compare itraconazole monotherapy with a combination of itraconazole and isotretinoin in adult patients with tinea corporis and/or tinea cruris. The study will evaluate treatment duration, cure rate, and safety profile of both regimens. The findings may provide evidence regarding the potential benefit of adding isotretinoin to conventional antifungal therapy and help optimize management strategies for adult patients with dermatophytosis.

Timeline

Start
2026-10-01
Primary completion
2027-03-01
Completion
2027-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Isotretinoin Other / unclassified 20 mg Oral
Subject Itraconazole Small molecule 200 mg Oral

Indications